IPX203与速释卡比多巴-左旋多巴治疗帕金森病运动波动的比较:RISE-PD随机临床试验
RISE-PD是一项20周、随机、双盲、双模拟、活性对照的3期试验,在美国和欧洲105个中心纳入630例有运动波动的帕金森病患者。506例随机接受IPX203(n=256)或速释卡比多巴-左旋多巴(n=250)治疗13周。IPX203较速释剂显著改善每日良好开期(最小二乘均值差0.53小时,95%CI 0.09-0.97,P=0.02),且给药频率更低(平均每日3次 vs 5次)。
要点
- IPX203较速释卡比多巴-左旋多巴显著增加每日良好开期0.53小时(95%CI 0.09-0.97,P=0.02)。
- IPX203平均每日给药3次,速释剂为5次,每剂良好开期增加1.55小时(95%CI 1.37-1.73,P<0.001)。
- 双盲期最常见不良事件为恶心(IPX203 4.3% vs 速释剂0.8%)和焦虑(2.7% vs 0.0%)。
核心结论
- 在有运动波动的帕金森病患者中,IPX203较速释卡比多巴-左旋多巴提供更多每日良好开期小时数,且给药频率更低。
研究设计与样本
- RISE-PD为20周、随机、双盲、双模拟、活性对照的3期临床试验,于2018年11月6日至2021年6月15日在美国和欧洲105个学术和临床中心进行。
- 筛查770例,排除140例(服用除每日睡前单次剂量外的控释卡比多巴-左旋多巴、Rytary(Amneal Pharmaceuticals)、额外卡比多巴或苄丝肼、或儿茶酚-O-甲基转移酶抑制剂,或过去10年内有精神病病史),纳入630例。
- 经过3周开放标签速释卡比多巴-左旋多巴剂量调整和4周转换为IPX203后,患者按1:1随机接受双盲双模拟的速释卡比多巴-左旋多巴或IPX203治疗13周。
主要发现
- 共630例患者入组(平均[SD]年龄66.5[8.95]岁;男性396例[62.9%]),506例随机接受IPX203(n=256)或速释卡比多巴-左旋多巴(n=250)。
- 主要终点达到:IPX203较速释卡比多巴-左旋多巴在每日良好开期(即无麻烦性异动症的开期)从基线至双盲治疗期末的平均变化方面显示统计学显著改善(最小二乘均值差0.53小时;95%CI 0.09-0.97;P=0.02)。
- IPX203平均每日给药3次,速释卡比多巴-左旋多巴为5次;每剂良好开期IPX203较速释剂增加1.55小时(95%CI 1.37-1.73;P<0.001)。
- 双盲期最常见不良事件(IPX203 vs 速释卡比多巴-左旋多巴)为恶心(4.3% vs 0.8%)和焦虑(2.7% vs 0.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Levodopa has a short half-life and a limited window of opportunity for absorption in the proximal small intestine. IPX203 is an oral, extended-release formulation of carbidopa-levodopa developed to address these limitations. OBJECTIVE: To assess the efficacy and safety of IPX203 vs immediate-release carbidopa-levodopa in patients with Parkinson disease who are experiencing motor fluctuations. DESIGN, SETTING, AND PARTICIPANTS: RISE-PD was a 20-week, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial. The study was conducted between November 6, 2018, and June 15, 2021, at 105 academic and clinical centers in the US and Europe. Patients with Parkinson disease taking a total daily dose of 400 mg or more of levodopa and experiencing an average of 2.5 hours or more daily off-time were included in the study. A total of 770 patients were screened, 140 were excluded (those taking controlled-release carbidopa-levodopa apart from a single daily bedtime dose, Rytary (Amneal Pharmaceuticals), additional carbidopa or benserazide, or catechol O-methyl transferase inhibitors or who had a history of psychosis within the past 10 years), and 630 were enrolled in the trial. INTERVENTIONS: Following open-label immediate-release carbidopa-levodopa dose adjustment (3 weeks) and conversion to IPX203 (4 weeks), patients were randomized in a 1:1 ratio to double-blind, double-dummy treatment with immediate-release carbidopa-levodopa or IPX203 for 13 weeks. MAIN OUTCOME AND MEASURES: The primary end point was mean change in daily good on-time (ie, on-time without troublesome dyskinesia) from baseline to the end of the double-blind treatment period. RESULTS: A total of 630 patients (mean [SD] age, 66.5 [8.95] years; 396 [62.9%] men) were enrolled, and 506 patients were randomly assigned to receive IPX203 (n = 256) or immediate-release carbidopa-levodopa (n = 250). The study met its primary end point, demonstrating statistically significant improvement in daily good on-time for IPX203 compared to immediate-release carbidopa-levodopa (least squares mean, 0.53 hours; 95% CI, 0.09-0.97; P = .02), with IPX203 dosed a mean 3 times per day vs 5 times per day for immediate-release carbidopa-levodopa. Good on-time per dose increased by 1.55 hours with IPX203 compared to immediate-release carbidopa-levodopa (95% CI, 1.37-1.73; P < .001). IPX203 was well tolerated. The most common adverse events in the double-blind phase (IPX203 vs immediate-release carbidopa-levodopa) were nausea (4.3% vs 0.8%) and anxiety (2.7% vs 0.0%). CONCLUSIONS AND RELEVANCE: In this study, IPX203 provided more hours of good on-time per day than immediate-release carbidopa-levodopa, even as IPX203 was dosed less frequently. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03670953.
引用
- Hauser RA, Espay AJ, Ellenbogen AL, et al. IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37578800. doi:10.1001/jamaneurol.2023.2679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。